The best way to beat cancer is to catch it early.
Advancing cancer screening with CDA technology and multi-disciplinary expertise.
Ticker Symbol: ANPC (NASDAQ Global Market)
Early cancer screening saves lives and dramatically reduces costs.
Results speak.
26
Cancer types detected
880+
Individuals screened out & identified with an early stage of disease
85-90%
Sensitivity & specificity for most cancer types
140,000+
General population screening & clinical research samples
Working together to achieve innovative, patented early disease screening and detection technology tools.
Co-Founder, Dr. Chris Yu and Dr. Herbert Yu are bringing together this multi-national team of medical, biomedical and nanotechnology scientists, and engineering experts. Their cross-disciplinary approach combines numerous fields of science, medicine and engineering to achieve our innovative, patented early cancer screening and detection technology.
“game changing”
CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.
Read the full article
“game changing”
CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.
Read the full article
Our Medical & Research Partners
Anpac Bio has partnered with respected medical and research institutions in China and the U.S., conducting multiple research studies. Anpac Bio scientists have published and presented research studies at the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit on Biomedical Sciences, among others.